自体血清滴眼液对原发性和继发性干燥综合征患者的临床疗效比较。

Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sjögren syndrome.

作者信息

Hwang Jehyung, Chung So-Hyang, Jeon Sohee, Kwok Seung-Ki, Park Sung-Hwan, Kim Man-Soo

机构信息

*Department of Ophthalmology, Sanggye Paik Hospital, Seoul, Korea; †Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ‡Catholic Institute of Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea; §Department of Medical Life Science, The Catholic University of Korea, Seoul, Korea; ¶Catholic High Performance Cell Therapy Center, The Catholic University of Korea, Seoul, Korea; and ‖Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

Cornea. 2014 Jul;33(7):663-7. doi: 10.1097/ICO.0000000000000147.

DOI:10.1097/ICO.0000000000000147

PMID:24886995

Abstract

PURPOSE

Autologous serum eye drops are considered to be safe and efficient for the treatment of dry eyes associated with Sjögren syndrome (SS). The purpose of this study was to compare the clinical efficacies of autologous serum eye drops in the management of primary and secondary SS.

METHODS

Patients with primary (n = 20; 35 eyes) and secondary (n = 14; 27 eyes) SS dry eye were included. Serum concentrations of proinflammatory cytokines [tumor necrosis factor α, interleukin (IL)-1β, IL-6, and IL-8] were measured by a multiplex immunobead assay. The ocular symptom scores, ocular staining grades, and tear break-up time were evaluated before and after 4 weeks of 50% autologous serum eye drop application.

RESULTS

At enrollment, patients with secondary SS had higher serum proinflammatory cytokine levels (tumor necrosis factor α, IL-1β, IL-6, and IL-8) than patients with primary SS (P < 0.01). After 4 weeks of autologous serum eye drop treatment, patients with primary SS had significantly improved ocular symptoms (P < 0.01), ocular surface staining grades (P < 0.01), and tear break-up time (P < 0.05). However, patients with secondary SS had no improvement (P > 0.05).

CONCLUSIONS

Our results suggest that autologous serum eye drops might not be effective for the treatment of secondary SS because of elevated serum proinflammatory cytokine levels.

摘要

目的

自体血清滴眼液被认为对于治疗与干燥综合征（SS）相关的干眼症安全且有效。本研究的目的是比较自体血清滴眼液在原发性和继发性SS治疗中的临床疗效。

方法

纳入原发性（n = 20；35只眼）和继发性（n = 14；27只眼）SS干眼症患者。通过多重免疫珠分析法测量促炎细胞因子[肿瘤坏死因子α、白细胞介素（IL）-1β、IL-6和IL-8]的血清浓度。在应用50%自体血清滴眼液4周前后，评估眼部症状评分、眼表染色分级和泪膜破裂时间。

结果

入组时，继发性SS患者的血清促炎细胞因子水平（肿瘤坏死因子α、IL-1β、IL-6和IL-8）高于原发性SS患者（P < 0.01）。自体血清滴眼液治疗4周后，原发性SS患者的眼部症状（P < 0.01）、眼表染色分级（P < 0.01）和泪膜破裂时间（P < 0.05）均有显著改善。然而，继发性SS患者无改善（P > 0.05）。